Komori
Results7681LEOCLAN Co.,Ltd.Trading & Wholesale

Financial Results Summary for the Fiscal Year Ending September 2026 [Japanese GAAP] (Consolidated)

For the fiscal year ended September 2026, revenue and operating income increased significantly, mainly due to the effect of adding 4 acquired companies to the scope of consolidation. For the fiscal year ending September 2027, the company expects higher revenue and operating income, and forecasts an increase in the annual dividend from ¥17 to ¥22.

Worth reading
51Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
118.3
Year-on-year change in revenue (%)
Wording
Conditional
How definitive the wording is.

Results for this period

Full year1 October 2025 to 30 September 2026ConsolidatedJapanese GAAP
Net Sales46,910Million yenYear on year +118.3%Progress 97.7%
Operating profit807Million yenYear on year +180.2%Progress 89.7%
Ordinary income748Million yenYear on year +142.5%Progress 88.0%
Net income attributable to owners of the parent346Million yenYear on year +126.9%Progress 69.2%

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share¥58.60
Operating Margin1.7%
Financial position at period-end
Total assets22,730Million yen
of which net assets 6,079 Million yenEquity ratio 25.9%vs. prior year-end -25.9pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Cash inflows and outflows
Operating+1,655
Investment-4,332
Financials+4,349
Net change+1,672

Stacked from zero: upward is an increase in cash, downward a decrease (in Million yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.

Cash and cash equivalents at end of period6,418 Million yen
Segment revenue
Medical Total Solution Business21,283,81347.3%+5.1%
Remote Diagnostic Imaging Services Business821,9901.8%
Minimally Invasive Medical Device Sales business22,279,82149.5%
Rental Business638,1171.4%
Segment profit
Medical Total Solution Business249,31632.1%-19.0%
Remote Diagnostic Imaging Services Business66,0998.5%-4.5%
Minimally Invasive Medical Device Sales business381,16849.0%
Rental Business81,24710.4%
Outlook and shareholder returns
Full-year earnings forecast
Net Sales48,000 Million yen (YoY +2.3%)
Operating profit900 Million yen (YoY +11.4%)
Ordinary income850 Million yen (YoY +13.5%)
Net income500 Million yen (YoY +44.2%)
Annual Dividend Forecast¥17.00 → ¥22.00
Payout ratiothe fiscal year ending September 2026 29.0% / Forecast for the fiscal year ending September 2027 26.1%
Factors Behind Changes in Business Performance

The factors affecting changes in results were the consolidation of Faskia Holdings Co., Ltd. and its 3 subsidiaries, increased revenue in other areas, a decrease in large projects associated with the construction, relocation and reorganization of medical institutions and other facilities, higher personnel expenses, and the absence of the impact of share acquisition-related expenses recognized in the fiscal year ended September 2026.

Disclosure regarding the going concern assumption

No material events or circumstances related to the going concern assumption, and no notes regarding the going concern assumption, apply.

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 4 / Company name ファスキアホールディングス株式会社, 株式会社フォーム, 株式会社シンコム, 中京三洋株式会社 / Excluded Number of companies 0 / Company name Not disclosed
Material subsequent eventsNo applicable items
Depreciation and amortization¥431,531 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors and analysts)
Issued Shares at Period-End5,922,000 shares
Treasury Shares at Period-End237 shares
Results for this period
ItemDetails
Fiscal Period ClassificationFull year
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedConsolidated
Period Covered1 October 2025 to 30 September 2026
Net Sales46,910 Million yen (YoY +118.3%)
Operating profit807 Million yen (YoY +180.2%)
Ordinary income748 Million yen (YoY +142.5%)
Profit attributable to owners of the parent346 Million yen (YoY +126.9%)
Net income per share¥58.60
Operating Margin1.7%
Equity ratioEnd of the current fiscal period 25.9% / End of previous period 51.8%
Total assets22,730 Million yen
Net assets6,079 Million yen
Cash flows from operating activities1,655 Million yen
Cash flows from investing activities-4,332 Million yen
Cash flows from financing activities4,349 Million yen
Cash and cash equivalents at end of period6,418 Million yen
Full-year earnings forecastNet Sales 48,000 Million yen (YoY +2.3%) / Operating profit 900 Million yen (YoY +11.4%) / Ordinary income 850 Million yen (YoY +13.5%) / Net income 500 Million yen (YoY +44.2%)
Annual Dividend Forecast¥17.00 → ¥22.00
Payout ratiothe fiscal year ending September 2026 29.0% / Forecast for the fiscal year ending September 2027 26.1%
Segment revenueMedical Total Solution Business ¥21,283,813 thousand (YoY +5.1%) / Remote Diagnostic Imaging Services Business ¥821,990 thousand / Minimally Invasive Medical Device Sales business ¥22,279,821 thousand / Rental Business ¥638,117 thousand
Segment profitMedical Total Solution Business ¥249,316 thousand (YoY -19.0%) / Remote Diagnostic Imaging Services Business ¥66,099 thousand (YoY -4.5%) / Minimally Invasive Medical Device Sales business ¥381,168 thousand / Rental Business ¥81,247 thousand
Depreciation and amortization¥431,531 thousand
Disclosure regarding the going concern assumptionNo material events or circumstances related to the going concern assumption, and no notes regarding the going concern assumption, apply.
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Changes in the scope of consolidationNew Number of companies 4 / Company name ファスキアホールディングス株式会社, 株式会社フォーム, 株式会社シンコム, 中京三洋株式会社 / Excluded Number of companies 0 / Company name Not disclosed
Material subsequent eventsNo applicable items
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors and analysts)
Issued Shares at Period-End5,922,000 shares
Treasury Shares at Period-End237 shares
Factors Behind Changes in Business PerformanceThe factors affecting changes in results were the consolidation of Faskia Holdings Co., Ltd. and its 3 subsidiaries, increased revenue in other areas, a decrease in large projects associated with the construction, relocation and reorganization of medical institutions and other facilities, higher personnel expenses, and the absence of the impact of share acquisition-related expenses recognized in the fiscal year ended September 2026.
Items this document does not state (6)
Revision to Earnings ForecastShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossBreakdown of extraordinary income (loss)

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The consolidation of Faskia Holdings Co., Ltd. and its 3 subsidiaries, increased revenue in other areas, and initiatives aimed at expanding the company’s scale and generating stable results contributed to higher revenue and earnings. Meanwhile, in the Medical Total Solutions business, lower profits were attributable to a decrease in large projects and higher personnel expenses.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results Summary for the Fiscal Year Ending September 2026 [Japanese GAAP] (Consolidated) | LEOCLAN Co.,Ltd. (7681) timely disclosure | Komori